Aβ aggregation and possible implications in Alzheimer's disease pathogenesis

•  Introduction •  Amyloid Structure •  Mechanism of Amyloid aggregation •  Aβ: a natively unfolded protein? •  Ambiguities in synthetic Ab studies •  Formation of Amyloid plaques •  Role of Ab in AD Pathogenesis •  Conclusion

[1]  P. Panegyres,et al.  The functions of the amyloid precursor protein gene. , 2011, Reviews in the neurosciences.

[2]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[3]  M. Albert,et al.  Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. , 2008, Archives of neurology.

[4]  H. Cai,et al.  The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2 , 2008, The Journal of Neuroscience.

[5]  Kim N. Green,et al.  Intracellular amyloid-β in Alzheimer's disease , 2007, Nature Reviews Neuroscience.

[6]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[7]  D. Holtzman,et al.  Apolipoprotein E and Low Density Lipoprotein Receptor-related Protein Facilitate Intraneuronal Aβ42 Accumulation in Amyloid Model Mice* , 2006, Journal of Biological Chemistry.

[8]  Florence Pasquier,et al.  Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.

[9]  Michael H. Hecht,et al.  Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Aβ42 peptide , 2006, Proceedings of the National Academy of Sciences.

[10]  M. Schrag,et al.  Deposition of iron and β‐amyloid plaques is associated with cortical cellular damage in rabbits fed with long‐term cholesterol‐enriched diets , 2006, Journal of neurochemistry.

[11]  P. Nandi,et al.  Osmolyte Trimethylamine N-Oxide Converts Recombinant α-Helical Prion Protein to its Soluble β-Structured Form at High Temperature , 2006 .

[12]  J. Busciglio,et al.  Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons , 2006, The Journal of Neuroscience.

[13]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[14]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[15]  A. Fink.  Natively unfolded proteins. , 2005, Current opinion in structural biology.

[16]  B. Winblad,et al.  Characterization of the Alzheimer's Disease-associated CLAC Protein and Identification of an Amyloid β-Peptide-binding Site* , 2005, Journal of Biological Chemistry.

[17]  C. Masters,et al.  Enhanced Toxicity and Cellular Binding of a Modified Amyloid β Peptide with a Methionine to Valine Substitution* , 2004, Journal of Biological Chemistry.

[18]  D. Michaelson,et al.  A nontransgenic mouse model shows inducible amyloid-β (Aβ) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade , 2004 .

[19]  Yonghe Li,et al.  The Low Density Lipoprotein Receptor-related Protein 1B Retains β-Amyloid Precursor Protein at the Cell Surface and Reduces Amyloid-β Peptide Production* , 2004, Journal of Biological Chemistry.

[20]  H. Dyson,et al.  The LEF-1 high-mobility group domain undergoes a disorder-to-order transition upon formation of a complex with cognate DNA. , 2004, Biochemistry.

[21]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[22]  L. Young,et al.  TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. , 2004, Cancer research.

[23]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[24]  A. Miranker,et al.  The mechanism of insulin action on islet amyloid polypeptide fiber formation. , 2004, Journal of molecular biology.

[25]  K. Hasegawa,et al.  Amyloid Fibril Formation in the Context of Full-length Protein , 2003, Journal of Biological Chemistry.

[26]  Gregory De Crescenzo,et al.  A Direct Interaction between Transforming Growth Factor (TGF)-βs and Amyloid-β Protein Affects Fibrillogenesis in a TGF-βReceptor-independent Manner* , 2003, Journal of Biological Chemistry.

[27]  Hoau Yan Wang,et al.  α7 Nicotinic Acetylcholine Receptors Mediate β-Amyloid Peptide-induced Tau Protein Phosphorylation* , 2003, Journal of Biological Chemistry.

[28]  B. Hyman,et al.  Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes , 2003, Journal of Cell Science.

[29]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[30]  J. Kelly,et al.  Amyloid as a natural product , 2003, The Journal of cell biology.

[31]  L. Hersh,et al.  Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Douglas R. McDonald,et al.  A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation , 2003, The Journal of Neuroscience.

[33]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[34]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Tycko.  Insights into the amyloid folding problem from solid-state NMR. , 2003, Biochemistry.

[36]  R. Nussinov,et al.  Extended disordered proteins: targeting function with less scaffold. , 2003, Trends in biochemical sciences.

[37]  B. Strooper,et al.  In Vitro Studies of Flemish, Dutch, and Wild-Type β-Amyloid Provide Evidence for Two-Staged Neurotoxicity , 2002, Neurobiology of Disease.

[38]  G. Damonte,et al.  Pyroglutamate‐modified amyloid β‐peptides – AβN3(pE) – strongly affect cultured neuron and astrocyte survival , 2002 .

[39]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[40]  C. Link,et al.  Interaction of intracellular β amyloid peptide with chaperone proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Nagao,et al.  Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23. , 2002, Biochemical and biophysical research communications.

[42]  Magnus Palmblad,et al.  Oxidation of Methionine 35 Attenuates Formation of Amyloid β-Peptide 1–40 Oligomers* , 2002, The Journal of Biological Chemistry.

[43]  Ling Xie,et al.  Alzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor , 2002, The Journal of Neuroscience.

[44]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[45]  M. D'Andrea,et al.  Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer’s disease , 2002, Neuroscience.

[46]  A. Corazza,et al.  The solution structure of human β2‐microglobulin reveals the prodromes of its amyloid transition , 2002, Protein science : a publication of the Protein Society.

[47]  D. Pogocki,et al.  Redox Properties of Met35 in Neurotoxic β-Amyloid Peptide. A Molecular Modeling Study , 2002 .

[48]  Christopher M. Dobson,et al.  Kinetic partitioning of protein folding and aggregation , 2002, Nature Structural Biology.

[49]  D. Selkoe,et al.  Intraneuronal Aβ42 accumulation in Down syndrome brain , 2002 .

[50]  D. Butterfield,et al.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. , 2001, Trends in molecular medicine.

[51]  V. Ferrans,et al.  β Amyloid peptide (Aβ42) is internalized via the G‐protein‐coupled receptor FPRL1 and forms fibrillar aggregates in macrophages1 , 2001 .

[52]  D. Holtzman.  Role of apoE/Aβ interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy , 2001, Journal of Molecular Neuroscience.

[53]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[54]  D. Small,et al.  Alzheimer's disease and Aβ toxicity: from top to bottom , 2001, Nature Reviews Neuroscience.

[55]  J. Cleary,et al.  Amyloid beta-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. , 2001, Journal of lipid research.

[56]  B. Strooper,et al.  Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability , 2001 .

[57]  Oliver Wirths,et al.  Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice , 2001, Neuroscience Letters.

[58]  M. Saraiva.  Transthyretin amyloidosis: a tale of weak interactions , 2001, FEBS letters.

[59]  T. Grabowski,et al.  Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy , 2001, Annals of neurology.

[60]  D. Elbaum,et al.  Oxidative and hydrolytic properties of β-amyloid , 2001 .

[61]  G. Di Chiara,et al.  Cocaine and Amphetamine Increase Extracellular Dopamine in the Nucleus Accumbens of Mice Lacking the Dopamine Transporter Gene , 2001, The Journal of Neuroscience.

[62]  C. Dobson,et al.  Amyloid fibril formation by a helical cytochrome , 2001, FEBS letters.

[63]  J. Troncoso,et al.  Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. , 2001, Archives of pathology & laboratory medicine.

[64]  P. Fraser,et al.  Amyloid-β Interactions with Chondroitin Sulfate-derived Monosaccharides and Disaccharides , 2001, Journal of Biological Chemistry.

[65]  P. Fraser,et al.  Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides. implications for drug development. , 2001, The Journal of biological chemistry.

[66]  W. Shen,et al.  Amyloid β42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1 , 2001, The Journal of Neuroscience.

[67]  N. Cairns,et al.  Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. , 2001, Biochemical and biophysical research communications.

[68]  D. Kirschner,et al.  Laminin inhibition of β‐amyloid protein (Aβ) fibrillogenesis and identification of an Aβ binding site localized to the globular domain repeats on the laminin a chain , 2000 .

[69]  T. Saido,et al.  Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.

[70]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Hecht,et al.  Nature disfavors sequences of alternating polar and non-polar amino acids: implications for amyloidogenesis. , 2000, Journal of molecular biology.

[72]  A Giuliani,et al.  The role of hydrophobicity patterns in prion folding as revealed by recurrence quantification analysis of primary structure. , 2000, Protein engineering.

[73]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[74]  W. Halfter,et al.  Agrin Binds to β-Amyloid (Aβ), Accelerates Aβ Fibril Formation, and Is Localized to Aβ Deposits in Alzheimer's Disease Brain , 2000, Molecular and Cellular Neuroscience.

[75]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[76]  P. Fraser,et al.  Manipulating the Amyloid-β Aggregation Pathway with Chemical Chaperones* , 1999, The Journal of Biological Chemistry.

[77]  F. Gejyo,et al.  Interaction between Aβ (1-42) and Aβ (1-40) in Alzheimer's β-amyloid fibril formation in vitro , 1999 .

[78]  C. Dobson.  Protein misfolding, evolution and disease. , 1999, Trends in biochemical sciences.

[79]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[80]  L. Tjernberg,et al.  Endogenous Proteins Controlling Amyloid β-Peptide Polymerization , 1999, Journal of Biological Chemistry.

[81]  L. Tjernberg,et al.  Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. , 1999, The Journal of biological chemistry.

[82]  R. Kisilevsky,et al.  The Heparin/Heparan Sulfate-binding Site on Apo-serum Amyloid A , 1999, The Journal of Biological Chemistry.

[83]  M Karplus,et al.  The fundamentals of protein folding: bringing together theory and experiment. , 1999, Current opinion in structural biology.

[84]  A. Roher,et al.  The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer’s Disease* , 1998, The Journal of Biological Chemistry.

[85]  Yu-Min Kuo,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[86]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[88]  R J Miller,et al.  Isoform-Specific Effect of Apolipoprotein E on Cell Survival and β-Amyloid-Induced Toxicity in Rat Hippocampal Pyramidal Neuronal Cultures , 1998, The Journal of Neuroscience.

[89]  D. Thal,et al.  The subunits of α 2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed α 2-macroglobulin and interleukin 6 in Alzheimer's disease , 1997, Brain Research.

[90]  S. Brining.  Predicting the In Vitro Toxicity of Synthetic Beta-Amyloid (1-40) , 1997, Neurobiology of Aging.

[91]  B. Gilchrest,et al.  Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. , 1997, The Journal of clinical investigation.

[92]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[93]  D. D'urso,et al.  Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[94]  W. Tourtellotte,et al.  Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[95]  M. F. Perutz,et al.  Mutations make enzyme polymerize , 1997, Nature.

[96]  J. Hainfeld,et al.  Binding of Amyloid β Protein to the 20 S Proteasome* , 1997, The Journal of Biological Chemistry.

[97]  B. Hyman,et al.  Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* , 1996, The Journal of Biological Chemistry.

[98]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[99]  P. Lansbury.  A Reductionist View of Alzheimer′s Disease , 1996 .

[100]  F. Maxfield,et al.  Microglial Cells Internalize Aggregates of the Alzheimer's Disease Amyloid β-Protein Via a Scavenger Receptor , 1996, Neuron.

[101]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[102]  D. Perlmutter,et al.  The Serpin-Enzyme Complex Receptor Recognizes Soluble, Nontoxic Amyloid-β Peptide but Not Aggregated, Cytotoxic Amyloid-β Peptide* , 1996, The Journal of Biological Chemistry.

[103]  Peter T. Lansbury,et al.  A REDUCTIONIST VIEW OF ALZHEIMER'S DISEASE , 1996 .

[104]  P. Greengard,et al.  Regulated Formation of Golgi Secretory Vesicles Containing Alzheimer β-Amyloid Precursor Protein (*) , 1995, The Journal of Biological Chemistry.

[105]  R. Murphy,et al.  Solvent effects on self-assembly of beta-amyloid peptide. , 1995, Biophysical journal.

[106]  L. Lovat,et al.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[107]  W. Honer,et al.  Correlations of synaptic and pathological markers with cognition of the elderly , 1995, Neurobiology of Aging.

[108]  G. Fasman,et al.  Solubilization of beta-amyloid-(1-42)-peptide: reversing the beta-sheet conformation induced by aluminum with silicates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[109]  W. Klein,et al.  Interaction of beta-amyloid peptides with integrins in a human nerve cell line , 1995, Neuroscience Letters.

[110]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[111]  C. Glabe,et al.  Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. , 1994, The Journal of biological chemistry.

[112]  P. Mcgeer,et al.  Two types of dystrophic neurites in senile plaques of alzheimer disease and elderly non-demented cases , 1994, Neuroscience Letters.

[113]  D. Walker,et al.  Involvement of microglia in Alzheimer's disease. , 1994, Neuropathology and applied neurobiology.

[114]  C. Masters,et al.  A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. , 1993, The Journal of biological chemistry.

[115]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[116]  K. Beyreuther,et al.  Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. , 1992, The Journal of biological chemistry.

[117]  P. May,et al.  β-amyloid peptide in vitro toxicity: Lot-to-lot variability , 1992, Neurobiology of Aging.

[118]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[119]  D. Selkoe,et al.  Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. , 1992, The Journal of biological chemistry.

[120]  M. Mizuguchi,et al.  Differential distribution of cellular forms of β-amyloid precursor protein in murine glial cell cultures , 1992, Brain Research.

[121]  G. Cole,et al.  Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. , 1992, The American journal of pathology.

[122]  J. Bauer,et al.  Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[123]  C. Cotman,et al.  Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. , 1992, The Journal of biological chemistry.

[124]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[125]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[126]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[127]  J. Hardy,et al.  Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). , 1990, Science.

[128]  I. Lieberburg,et al.  Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. , 1990, Science.

[129]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[130]  D. Mann,et al.  A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease , 1987, Journal of the Neurological Sciences.

[131]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[132]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[133]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[134]  I. Macreadie,et al.  A New Method to Measure Cellular Toxicity of Non-Fibrillar and Fibrillar Alzheimer's Aβ Using Yeast , 2008 .

[135]  G. Cole,et al.  Phagocytosis and Deposition of Vascular -amyloid in Rat Brains Injected with Alzheimer -amyloid , 2007 .

[136]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[137]  R. Murphy,et al.  Solvent Effects on Self-Assembly of 1B-Amyloid Peptide , 2005 .

[138]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[139]  D. Pogocki,et al.  Redox properties of Met(35) in neurotoxic beta-amyloid peptide. A molecular modeling study. , 2002, Chemical research in toxicology.

[140]  Christopher M Dobson,et al.  Getting out of shape. , 2002, Nature.

[141]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[142]  C. Schultz.  Illuminating folding intermediates , 2000, Nature Structural Biology.

[143]  J. Buxbaum,et al.  The genetics of the amyloidoses. , 2000, Annual review of medicine.

[144]  D. Ron,et al.  Conformational disease , 2000, Nature Cell Biology.

[145]  A Hofman,et al.  Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. , 1998, Human molecular genetics.

[146]  D. Thal,et al.  The subunits of alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed alpha2-macroglobulin and interleukin 6 in Alzheimer's disease. , 1997, Brain research.

[147]  M. Perutz.  Amyloid fibrils. Mutations make enzyme polymerize. , 1997, Nature.

[148]  C. Blake,et al.  The structure of amyloid fibrils by electron microscopy and X-ray diffraction. , 1997, Advances in protein chemistry.

[149]  M. Adams,et al.  The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families , 1995, Nature Genetics.

[150]  A. Hofman,et al.  Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β–amyloid precursor protein gene , 1992, Nature Genetics.

[151]  A. Nappi,et al.  Alzheimer ' s Disease : Cell-Specific Pathology Isolates the Hippocampal Formation , 2022 .